

Supplementary Table S1A. The demographic and clinical features of the enrolled patients (n=222).

No. of Variables	No. of Values
Gender	
Gender	Frequency
Male	61%
Female	39%
Age, years	
Age	Frequency
<30	15
31-50	112
51-70	90
>70	05
Average	49.03
Range-years \pm SD	19-91 \pm 12.65
Healthy control (52)	
Gender	Frequency
Male	28 (54%)
Female	24 (46%)
Average age	40
Mean \pm SD- years	40 \pm 12.20
Age, years	
<30	15(29%)
31-50	26(50%)
51-70	10(19%)
>70	1(2%)
HCV infected patients	
Mild (n)	37
mean \pm SD years	50.56 \pm 13.19
mode	50
Moderate (n)	87
mean \pm SD years	47.18 \pm 12.25
Mode	55
Severe (n)	98
mean \pm (SD years	48.0 \pm 11.94
mode	50

Child Turcotte Pugh Score		
Child score A (5-6)	17%	
Child score A (7-9)	39%	
Child score A (10-15)	44%	
Ascites		
Male	High	38.2%
	Moderate	16.9%
	Less	4.5%
Female	High	20.6%
	Moderate	13.5%
	Less	6.4%
Blood pressure		
Male	Normal	18%
	High	15.4%
	Low	26.2%
Female	Normal	15%
	High	10.9%
	Low	14.6%
Size of spleen		
Male	Normal	21%
	Enlarged	38.6%
Female	Normal	15%
	Enlarged	25.5%
GIT		
Male	Normal	4%
	Tenderness	21.3%
	Non-tenderness	37.8%
Female	Normal	7%
	Tenderness	12%
	Non-tenderness	27.7%
Viral load (Iu/ml)		
<10,00000	49.4%	
10,00000 -50,00000	26.21%	
>50,00000	24.34%	

Abbreviation: GIT; gastro-intestinal tract.

Supplementary Table S1B. LFTs, Genotypes, Risk factors of chronic HCV Patients.

ALT/AST		
Average –Median	121.46 – 121	
Mode	139	
Range ± Standard deviation	64-186 ± 29.23	
AFP		
<40 ng/mL	33%	
41-150 ng/mL	47%	
>151 ng/mL	30%	
Mean	43.09	
Range ± Standard deviation	16-301±28.08	
Albumin		
Male	Normal (3-5 g/dL)	15.7%
	Abnormal (<3-5 g/dL)	24.7%
Female	Normal (3-5 g/dL)	19.1%
	Abnormal (<3-5 g/dL)	40.4%
Risk factors		
Dentist	33.08%	
Unknown source	28.95%	
Surgery	10.86%	
HCV in family	23.97%	
Blood Transfusion	4.11%	
Genotypes		
Genotype 1	11(5)	
Genotype 2	23(10.4)	
Genotype 3	137(61.7)	
Mixed	9(4.1)	
Untyped	42(18.9)	
Viral load (Iu/ml)		
<10,00000	49.4%	
10,00000 -50,00000	26.21%	
>50,00000	24.34%	

Abbreviation: ALT; alanine aminotransferase. AST; aspartate aminotransferase. AFP; alpha fetoprotein. ALP; alkaline phosphatase

Supplementary Table S1C. List of healthy control (n=52) used in the HCV study.

S.No	Age	Gender	Area
1	50	F	Peshawar
2	48	M	Charsada
3	30	F	Peshawar
4	33	M	Peshawar
5	43	M	Peshawar
6	33	F	Peshawar
7	35	F	Mardan
8	60	M	Peshawar
9	40	F	Peshawar
10	55	M	Peshawar
11	65	M	Peshawar
12	48	M	Charsada
13	30	F	Peshawar
14	29	F	Mardan
15	50	M	Peshawar
16	50	M	Peshawar
17	40	F	Peshawar
18	35	F	Mardan
19	61	M	Peshawar
20	28	F	Peshawar
21	25	M	Peshawar
22	39	F	Peshawar
23	44	M	Peshawar
24	25	F	Peshawar
25	50	M	Peshawar
26	45	M	Peshawar
27	30	M	Charsada
28	79	F	Peshawar
29	40	M	Mardan
30	49	M	Peshawar
31	30	M	Peshawar
32	62	M	Peshawar
33	30	F	Peshawar
34	45	F	Malakand
35	45	M	Peshawar
36	36	M	Peshawar
37	40	F	Peshawar
38	44	M	Mardan
39	52	F	Mardan

40	30	F	Swabi
41	40	M	Peshawar
42	40	F	Mardan
43	52	M	Charsada
44	50	F	Charsada
45	23	F	Peshawar
46	22	M	Mardan
47	40	F	Peshawar
48	39	M	Kohat
49	23	F	Mardan
50	20	F	Peshawar
51	45	M	Kohat
52	27	M	Peshawar

Supplementary Table S2. MicroRNA- 192 performance in HCV patient.

Parameters	Area under the ROC curve	95% confidence interval	Std. Error	P value
Control- Mild	0.7625	0.6331 to 0.8919	0.06601	< 0.0005
Control- Moderate	0.6590	0.5601 to 0.7579	0.05046	< 0.0028
Control- Severe	0.7076	0.6209 to 0.7942	0.04420	< 0.0001
Mild- Moderate	0.6123	0.4705 to 0.7541	0.07231	0.1320
Mild- Severe	0.7625	0.6331 to 0.8919	0.06601	< 0.0005
Moderate- Severe	0.5555	0.4624 to 0.6485	0.04747	0.2405

Supplementary Table S3. MicroRNA- 29a diagnostic performance in HCV patient.

Parameters	Area under the ROC curve	95% confidence interval	Std. Error	P value
Control- Mild	0.8349	0.7181 to 0.9517	0.05958	< 0.0010
Control- Moderate	0.8588	0.7791 to 0.9386	0.04067	< 0.0001
Control- Severe	0.7862	0.6834 to 0.8889	0.05241	< 0.0001
Mild- Moderate	0.6081	0.4264 to 0.7899	0.09271	0.2905
Mild- Severe	0.8349	0.7181 to 0.9517	0.05958	0.05958
Moderate- Severe	0.7462	0.6308 to 0.8616	0.05886	0.00010




Figure S1. microRNA-192.





Figure S2. microRNA-29a.



ROC-192

Figure S3. ROC-192.




Figure S4. ROC-29a